Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. Richard M. Stone on the Genetic Landscape in AML

October 6th 2016

Richard M. Stone, MD, chief of staff, program director, adult leukemia, institute physician, professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses what is currently understood regarding the genetic landscape in acute myeloid leukemia (AML).

Dr. Horwitz on Combination CHOP Regimens in Peripheral T-cell Lymphoma

October 5th 2016

Steven M. Horwitz, MD, medical oncologist, Memorial Sloan Kettering, discusses the evolving role of CHOP in peripheral T-cell lymphoma. For years CHOP or a similar regimen has been the standard treatment for peripheral T-cell lymphoma.

Novel Agents Hold Significant Promise in Treatment of AML

October 1st 2016

Jessica K. Altman, MD, discussed the potential of agents poised to transform the landscape of acute myeloid leukemia.

Incorporating Generic Imatinib Into Frontline Treatment for CML

October 1st 2016

As generic imatinib enters the market, new questions focus on a renewed role for the agent in conjunction with second-generation TKIs.

Dr. Jerald Radich on Impact of Generic Imatinib in CML

October 1st 2016

Jerald P. Radich, MD, clinical research division, Fred Hutchinson Cancer Research Center, discusses the impact of the approval of generic imatinib in chronic myelogenous leukemia (CML).

Unmet Needs in Polycythemia Vera

September 29th 2016

Role of Ruxolitinib in Polycythemia Vera

September 29th 2016

Looking Beyond Hematocrit Control in Polycythemia Vera

September 29th 2016

Polycythemia Vera: Considerations in Hematocrit Control

September 29th 2016

Patient Selection for Treatment of Polycythemia Vera

September 29th 2016

Assessing Risk in Polycythemia Vera

September 29th 2016

Understanding Polycythemia Vera

September 29th 2016

Unmet Needs in Myelofibrosis

September 29th 2016

Therapeutic Response with JAK Inhibition in Myelofibrosis

September 29th 2016

Cytopenia-Related Considerations in Myelofibrosis

September 29th 2016

Optimal Timing of JAK Inhibition in Myelofibrosis

September 29th 2016

Role for JAK Inhibition in Myelofibrosis

September 29th 2016

Myelofibrosis: Considerations for Transplant or Surgery

September 29th 2016

When to Initiate Therapy in Myelofibrosis

September 29th 2016

Practical Risk Assessment in Myelofibrosis

September 29th 2016